

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 July 2021 (15.07.2021)



(10) International Publication Number
WO 2021/142307 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C12N 15/113 (2010.01)
A61K 39/395 (2006.01) A61P 21/00 (2006.01)

(21) International Application Number:

PCT/US2021/012756

(22) International Filing Date:

08 January 2021 (08.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/959,796	10 January 2020 (10.01.2020)	US
62/965,748	24 January 2020 (24.01.2020)	US
62/968,443	31 January 2020 (31.01.2020)	US
62/980,874	24 February 2020 (24.02.2020)	US
63/055,537	23 July 2020 (23.07.2020)	US
63/069,066	23 August 2020 (23.08.2020)	US
63/132,929	31 December 2020 (31.12.2020)	US

(71) Applicant: **DYNE THERAPEUTICS, INC.** [US/US];
830 Winter Street, Waltham, MA 02451 (US).

(72) Inventors: **SUBRAMANIAN, Romesh, R.**; 9 Alan Street,
Framingham, MA 01701 (US). **QATANANI, Mohammed,**
T.; 830 Winter Street, Waltham, MA 02451 (US). **WEE-**
DEN, Timothy; 830 Winter Street, Waltham, MA 02451
(US). **DESJARDINS, Cody, A.**; 830 Winter Street,
Waltham, MA 02451 (US). **QUINN, Brendan**; 830 Winter
Street, Waltham, MA 02451 (US). **RHODES, Jason, P.**;
830 Winter Street, Waltham, MA 02451 (US).

(74) Agent: **GE, Zhiyun** et al.; Wolf, Greenfield & Sacks, P.C.,
600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES




FIG. 16

(57) Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.